Abstract:Aim: To discover novel ligands of estrogen receptor (ER) β using pharmacophore mapping and structure-based screening. Methods: A computer-aided strategy combining pharmacophore mapping and structure-based screening was used to screen the Maybridge and Enamine databases. Yeast two-hybrid (Y2H) assay was used to detect the activity and selectivity of the chosen compounds. The transcriptional activities of the chosen compounds were demonstrated with luciferase reporter assays. The anti-proliferative effects of ER antagonists against MCF-7 and MDA-MB-231 breast cancer cells were examined using MTT assay, and the mechanisms of action were analyzed with flow cytometry analysis and Western blotting. Results: Through in silico screen, 95 compounds were chosen for testing in Y2H assay, which led to 20 potent ligands, including 10 agonists, 8 antagonists and 2 partial agonists with EC 50 or IC 50 values at μmol/L. Furthermore, 6 agonists exhibited absolute selectivity for ERβ, and 3 agonists showed higher selectivity for ERβ. The agonists 1g and 1h (10, 25, and 50 μmol/L) dose-dependently increased ER transcriptional activities, whereas the antagonists 2a and 2d (10, 25, and 50 μmol/L) caused dose-dependent inhibition on the activities. The antagonists and partial agonists at 100 μmol/L suppressed the proliferation of ERα positive MCF-7 cells and ERβ positive MDA-MB-231 cells, but were more effective against MDA-MB-231 cells. Treatment of MDA-MB-231 cells with antagonists 2a and 2d (25 and 50 μmol/L) dose-dependently increased the population of cells in the S phase. Both 2a and 2d treatment dose-dependently decreased the expression levels of cyclin A and CDK2. Meanwhile, the downregulation of cyclin E was only caused by 2d , while 2a treatment did not cause significant changes in the protein levels of cyclin E. Conclusion: The selective ligands discovered in this study are promising drug candidates to be used as molecular probes to explore the differences between ERα and ERβ.

1-Phenyl-4-benzoyl-1h-1,2,3-triazoles As Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor Α

1-Benzyl-4-phenyl-1h-1,2,3-triazoles Improve the Transcriptional Functions of Estrogen-Related Receptor Γ and Promote the Browning of White Adipose.

Benzothiophene Derivatives As Selective Estrogen Receptor Covalent Antagonists: Design, Synthesis and Anti-Erα Activities.

Identification of Pyrido[1,2-α]pyrimidine-4-ones As New Molecules Improving the Transcriptional Functions of Estrogen-Related Receptor Α

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Development of Thieno[3 ',2 ':5,6]Thiopyrano[4,3-C]pyrazole-3-carboxamide Derivatives As the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity

Selective Ligands of Estrogen Receptor Β Discovered Using Pharmacophore Mapping and Structure-Based Virtual Screening.

Discovery of Thieno[2,3-e]indazole Derivatives As Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability

A New Class of 1,3,5-Triazine-based Selective Estrogen Receptor Degraders (serds): Lead Optimization, Molecular Docking and Dynamic Simulation.

Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Identification of New Small-Molecule Inducers of Estrogen-related Receptor Α (errα) Degradation

Synthesis and Biological Evaluation of Aromatase Inhibitors

Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells

Synthesis and Biological Evaluation of 3-Aryl-quinolin Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: an Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators Against Endocrine-Resistant Breast Cancer.